News & Updates

The presence of coexisting clinical depression and anxiety (DA) is not uncommon in the primary care setting, particularly among younger individuals, patients with diabetes, and women, a Singapore study has shown.

A two-component nutritional strategy is as effective as the established dietary intervention for blood pressure (BP) control in individuals with hypertension, results of the NUPRESS study have shown.

A 12-week lifestyle intervention comprising a moderate-intensity physical activity (PA) programme and a hypocaloric Mediterranean diet (MD) promoted fat removal and liver fibrosis improvement in individuals with metabolic dysfunction-associated steatotic liver disease (MASLD), findings from the EHmet-DIA study suggest.

Treatment with obeticholic acid (OCA) improves clinical outcome in patients with precirrhotic fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH), with a reduction in histological progression to cirrhosis seen in those receiving the 25-mg dose, as seen in the final results of the REGENERATE study.

Patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH) and fibrosis treated with resmetirom achieve NASH resolution with no fibrosis worsening (NR) or ≥1-stage fibrosis improvement with no worsening of the NAS score (FI), according to the results of the ongoing MAESTRO-NASH study.

An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.